alternative to tirzepatide Eli Lilly sues companies selling

The FDA has reviewed Eli Lillys injectable tirzepatide products, Mounjaro and Zepbound, for safety and effectiveness

Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study

Those who continued to take Zepbound lost an additional 5.5 percent of their weight (on top of the 20.9 percent they already lost), while those who went on placebo regained about half the weight they lost over the course of the year meaning they were still down nearly 10 percent compared with their original weight

Rising demand for premium, clean-label, and vegan supplements

Red flags present

Ivy Shi, who is a resident in internal medicine at BIDMC, worked with Kazi to produce the analysis